Oxford Asset Management’s Precigen PGEN Stock Holding History

Oxford Asset Management’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-56,392	Closed	-$369K	–	1902
2018 Q4	$369K	Buy	+56,392	New	+$632K	0.01%	1322
2016 Q1	–	Sell	-16,763	Closed	-$522K	–	870
2015 Q4	$522K	Buy	+16,763	New	+$565K	0.01%	665

Other funds holding PGEN

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Oxford Asset Management's PGEN Position: Q1 2019 in Review

Oxford Asset Management sold out of Precigen (PGEN) in Q1 2019, closing a stake of 56,392 shares — an estimated $369K sold.

Oxford Asset Management first reported a position in PGEN in Q4 2015 and held it in 2 quarters. The position peaked at $522K in Q4 2015. 166 funds tracked by Wall St. Rank hold PGEN as of Q1 2019.

Oxford Asset Management reported no remaining Precigen position as of Q1 2019 after selling out during the quarter.
Oxford Asset Management sold 56,392 Precigen shares in Q1 2019, an estimated $369K.
Oxford Asset Management first reported a position in Precigen in Q4 2015 and held it in 2 quarters.
Oxford Asset Management's Precigen position peaked at $522K in Q4 2015.
166 funds tracked by Wall St. Rank held Precigen as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.